Navigation Links
Report Confirms Source of Contaminated Heparin

A man-made chemical was added to the blood thinner imported from China

WEDNESDAY, Dec. 3 (HealthDay News) -- A final report on the deadly contamination of the blood thinner heparin confirms that the problem was caused by a man-made chemical that was added to batches of the drug imported from China, U.S. investigators report.

The crisis, which began last November, resulted in 152 adverse reactions and as many as 81 deaths in the United States. The Chinese heparin, contaminated with the chemical oversulfated chondroitin sulfate, was found in at least 10 countries, according to federal officials.

"The last case was reported on January 31," said Dr. Priti R. Patel, a medical epidemiologist with the U.S. Centers for Disease Control and Prevention, and a member of the investigation team that wrote the report.

Published in the Dec. 4 issue of the New England Journal of Medicine, the report "describes the adverse reactions caused by the contaminant" and links it to a specific substance, Patel said. The reactions included a drastic drop in blood pressure, nausea and shortness of breath, starting within 30 minutes after the administration of the heparin.

"There is a definite link between this contaminant and the patients who had these reactions," she said.

The first reports of such reactions among hospital patients given heparin came in November 2007. Eventually, cases were reported in 13 states. Investigators found a common thread in those cases: heparin marketed by Baxter Healthcare, of Deerfield, Ill., which got its supplies from China.

Raw heparin is derived from pig intestines. It is given intravenously to prevent blood clots during certain kinds of surgery, and also is used by people with kidney disease requiring dialysis. In China, heparin often is made by small, unregulated companies.

Chondroitin sulfate is a natural substance extracted from animal cartilage that can be used in supplements to treat arthritic joints. Oversulfation results from processing of the substance. Most of the reactions reported in the United States occurred in dialysis centers among people given high initial doses of heparin, the report found.

The heparin incident illustrates the importance of health providers reporting untoward incidents to regulatory authorities, Patel said. "Public health always relies on providers to make these reports," she said. "If they don't report, we have no way of finding what is wrong and correcting it. We are always asking people to be on their toes and communicate any problems."

Meanwhile, a letter in the same issue of the journal described a much easier way of identifying oversulfated chondroitin sulfate (OSCS) contamination in heparin -- should it occur again.

The two tests now mandated to detect contamination -- capillary electrophoresis and nuclear magnetic resonance spectroscopy -- are "technically challenging, not widely established and not easily applicable in clinical practice," said the letter from researchers at Christian-Albrechts University in Kiel, Germany.

That letter reported successful identification of OSCS contamination in heparin by use of one of the most common tests in medical practice --measuring prothrombin time, the time required for blood to clot, or coagulate. Studies show that coagulation time goes down as the amount of OSCS in a blood sample goes up, the letter said.

The test is widely available because many people, such as those taking the blood-thinning drug Coumadin for conditions such as atrial fibrillation, must have their clotting time assessed periodically.

"This test is applicable for any clinical laboratory, in the United States and Europe," said Susannne Alban, a professor of pharmacy and co-author of the letter. "It could be used as a pre-test, to detect the problem before any symptoms are seen."

More information

The U.S. National Library of Medicine describes the benefits and possible dangers of heparin.

SOURCES: Priti R. Patel, M.D., medical epidemiologist, U.S. Centers for Disease Control and Prevention, Atlanta; Susanne Alban, Pharm.D., professor, pharmacology, Christian-Albrechts-University, Kiel, Germany; Dec. 18, 2008, New England Journal of Medicine

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Virginia Tech Report Has National Importance
2. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
3. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
4. Haemacure Reports Third Quarter 2007 Results
5. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
6. Biotech Finishes on a High in August, Burrill Report Says
7. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
8. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
9. MDS Reports Third Quarter 2007 Results
10. First New York/New Jersey Health Care Report Card Released
11. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... Next IT Healthcare, the leader in patient ... year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher of ... the category of Digital Solutions for its innovative, industry-leading product, Alme Health Coach. ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Lutronic, a ... of Clarity, the latest addition to the devices for sale in the United States. ... nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... SACC-GA and SACC-USA through membership and leadership since 2008. Gary Bruce, President ... SACC-USA . Gary has spent a significant amount of time in Sweden ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., ... largest order to date. , The order will be from the China Disabled ... Cochlear Implant System is an effective solution for children and adults suffering from ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Sensor Networks, a leader in intelligent sensors and analytic software for sensor network-based systems, announced ... data collection of vital signs. Photo - ... ... ... ...
(Date:12/1/2015)... , Dec. 1, 2015 Ampio Pharmaceuticals, ... York Stock Exchange has established January 5, 2016 as the ... stockholders of the shares of Common Stock of Aytu ... share of Aytu common stock for every five (5) ... record date, December 1, 2015. The distribution date will be ...
(Date:12/1/2015)... Sweden , December 1, 2015 ... International Breast Cancer Study Group (IBCSG, Bern ... ) to be part of a state of the ... cancer drug.  --> --> ... cancer being treated with anti-hormonal therapy in combination with palbociclib, ...
Breaking Medicine Technology: